Trials / Completed
CompletedNCT01635764
Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa
A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 508 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study to evaluate the long term safety, tolerability and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa (HS).
Detailed description
HS is a painful, chronic skin disease characterized by recurrent inflamed nodules and abscesses, which may rupture to form fistulas and subsequent scarring. This study is an open-label extension study available to subjects who participated in a prior adalimumab study who meet all the inclusion and none of the exclusion criteria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | adalimumab | Adalimumab pre-filled syringe, administered by subcutaneous injection |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2012-07-10
- Last updated
- 2018-01-24
- Results posted
- 2017-09-05
Source: ClinicalTrials.gov record NCT01635764. Inclusion in this directory is not an endorsement.